



## 6th ICTHIC Scientific Program

**Friday, April 20th, 2012**

2.00 - 2.15 pm **Congress Opening:** A. Falanga, F.R. Rickles, B. Brenner

2.15 - 4.30 pm **Plenary Session 1: Epidemiology and risk factors of venous thromboembolism**

*Chairs: H.A. Liebman (USA), I. Pabinger (Austria)*

**PL01** Predictive potential of hemostatic biomarkers

*C. Ay (Austria)*

**PL02** Update on thrombotic risk stratification

*A. Khorana (USA)*

**PL03** Unsuspected PE in cancer patients

*M. Monreal (Spain)*

**PL04** Cancer in pregnancy

*B. Brenner (Israel)*

**OC01** Rate of venous thromboembolism by cancer type compared to the general population using multiple linked databases.

*A.J. Walker, J. West, T.R. Card, C. Crooks, M.J. Grainge. (UK)*

**OC02** Thromboembolic complications in children with cancer: data from the italian registry of childhood thrombosis (RITI)

*M.C. Putti, C. Gentilomo, E. Cavaliere, P. Saracco, P. Giordano, A.C. Molinari, M. Grassi, V. Buccella, A. Falanga, D. Sperli, P. Simioni e il Gruppo Italiano per il Registro Trombosi Infantile (GIRTI). (Italy)*

5.00 - 7.15 pm **Plenary Session 2: Genomics and proteomics of the hemostatic system in cancer**

*Chairs: M.-M. Samama (France), M. Cattaneo (Italy)*

**PL05** Genetic pathways linking hemostasis and cancer

*J. Rak (Canada)*

**PL06** Platelet CLEC-2 in lymphangiogenesis and cancer metastasis

*S.P. Watson (UK)*

**PL07** The platelet proteome

*W.F. Bahou (USA)*

**PL08** Akt and Ras pathways and modulation of TF expression in glioblastoma

*D. Brat (USA)*

**OC03** TrypsinogenIV, a new player in tumor angiogenesis.

*C. Ghilardi, S. Figini, M. Lupi, R. Fruscio, R. Giavazzi and M.R. Bani. (Italy)*

**OC04** Novel functions of TFPI isoforms in breast cancer cells.

*B. Stavik, G. Skretting, M. Tinholt, M. Sletten, P. Sandset, N. Iversen. (Norway)*

**7.30 pm Second Simon Karpatkin Memorial Lecture***Introduction F.R. Rickles (USA)*

Hemostasis, innate immunity and malignancy

J.L. Degen (USA)

**Saturday, April 21st, 2012****8.15 - 10.30 am Plenary Session 3 : Bleeding complications in cancer patients***Chairs: C.M. Kessler (USA), C. Velati (Italy)***PL09** Side effects of anti-angiogenic drugs

F. Rodeghiero (Italy)

**PL10** Diagnosis and treatment of disseminated intravascular coagulation

C.-H. Toh (UK)

**PL11** Transfusion issues in the cancer patient

A.B. Federici (Italy)

**PL12** Acquired hemophilias in cancer

N.S. Key (USA)

**OC05 Bleeding complications in patients with CKD and malignancy during anticoagulant treatment for venous thromboembolism.**J. Kooiman, P.L. den Exter, A. Gedik, J Hooijer, M.V. Huisman. (*The Netherlands*)**OC06 Evaluation of platelet function and thromboxane A2 production in aspirin-treated patients with essential thrombocythemia.**F. Lussana, E.A. Femia, M. Pugliano, G. Podda, C. Razzari, N. Maugeri, A. Lecchi, G. Motta, S. Caberlon, G. Gerli, M. Cattaneo. (*Italy*)**11.00 am - 1.15 pm Plenary Session 4: Coagulation and cancer progression***Chairs: M.B. Donati (Italy), R. Labianca (Italy)***PL13** The respective roles of TF isoforms in cancerH.H. Versteeg (*Netherlands*)**PL14** Heparanase procoagulant activityY. Nadir (*Israel*)**PL15** Protein C and cancerC.A. Spek (*Netherlands*)**PL16** Accounting for death as a competing risk in cancer VTE studies

J.I. Zwicker (USA)

**OC07 Binding of anti-GRP78 autoantibodies to cell surface GRP78 promotes cancer progression by activating tissue factor procoagulant activity.**A.A. Al-Hashimi, F. Majeed, M. Gonzalez-Gronow, R.C. Austin. (*Canada, USA*)



**OC08 Studying cell-microenvironment interactions in a microfluidics model of tumor microcirculation.**

Z.N. Demou, V. Turitto. (USA)

2.15 - 4.30 pm **Plenary Session 5: Hematological disorders**

*Chairs: G.H. Lyman (USA), R. Giavazzi (Italy)*

**PL17 Risk and management of thrombosis in multiple myeloma**

F.W. Leebeek (Netherlands)

**PL18 The role of JAK-2 inhibition**

A. Rambaldi (Italy)

**PL19 Splanchnic vein thrombosis: New risk factors and management**

W. Ageno (Italy)

**PL20 Heparin-induced thrombocytopenia in cancer**

P.M. Sandset (Norway)

**OC09 New potential markers of severe thrombo-hemorrhagic syndrome (THS) in acute promyelocytic leukemia (APL) patients: activated FVII-antithrombin complex (FVIIa-AT) and Tissue Factor (TF) mRNA**

M. Marchetti, L. Russo, C.J. Tartari, B. Woodhams, E. Di Bona, A. Rambaldi, F. Lo Coco and A. Falanga. (Italy)

**OC10 The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT).**

T.E. Warkentin, R. Sarode, M.A. Johnston, M.A. Crowther. (USA)

5.00 - 7.15 pm **Plenary Session 6: Anticoagulants and cancer**

*Chairs: S. Schulman (Canada), H.R. Büller (Netherlands)*

**PL21 New and old anticoagulants in cancer**

G. Agnelli (Italy)

**PL22 Guidelines for antithrombotics in cancer patients**

D. Farge-Bancel (France)

**PL23 Measurement of new oral anticoagulants**

J. Harenberg (Germany)

**PL24 LMWH and survival in lung cancer**

S. Noble (UK)

**OC11 The effect of aspirin on cancer mortality**

T. Meade (UK)

**OC12 New antithrombotic agents in the treatment of VTE; a subgroup analysis of the Phase III randomized clinical trials.**



G.T. Gerotziapas, M.M. Samama, I. Elalamy. (*France*)

### Sunday, April 22nd, 2012

#### 8.15 - 10.30 am **Plenary Session 7: Platelets and vascular endothelium**

*Chairs: C.W. Francis (USA), H. ten Cate (Netherlands)*

**PL25** The role of thrombomodulin in tumor growth and metastasis

N. Horowitz (*Israel*)

**PL26** Endothelial cell activation markers in cancer

A.D. Blann (*UK*)

**PL27** Novel functions of tissue factor in thrombosis and in cancer

W. Ruf (*USA*)

**PL28** Microparticles in tumor progression

A. Falanga (*Italy*)

#### **OC13 On the use of anti-platelet drugs to diminish both tumor growth and thrombosis.**

R. Darbousset, S. Mezouar, R. Bonier, V. Sbarra, D. Farge-Bancel, C. Frère, C. Dubois, L. Panicot-Dubois (*France*).

#### **OC14 Cellular origin and procoagulant activity of tissue factor-exposing microparticles in cancer patients.**

A. Kleinjan, R.J. Berckmans, A.N. Böing, A. Sturk, H.R. Büller, P.W. Kamphuisen, R. Nieuwland (*The Netherlands*)

#### 11.00 am - 1.15 pm **Plenary Session 8: Prevention and treatment of thrombosis**

*Chairs: M.N. Levine (Canada), P. Prandoni (Italy)*

**PL29** Thromboprophylaxis in the cancer surgical patient

A.K. Kakkar (*UK*)

**PL30** Thromboprophylaxis in non-surgical cancer patient

A.T. Cohen (*UK*)

**PL31** Treatment of established thrombotic events

A.Y. Lee (*Canada*)

**PL32** Overview of thrombosis and cancer survival

N. Kuderer (*USA*)

#### **OC15 Use of vena cava filters in cancer patients in California.**

R.H. White, A. Brunson, S. Murin, D.J. Tancredi, T. Wun. (*USA*)

#### **OC16 Incidence of venous thromboembolism in patients undergoing laparoscopic surgery for colorectal cancer.**

M.C. Vedovati, C. Becattini, F. Rondelli, M. Boncompagni, G. Camporese, R. Balzarotti, E. Mariani, O. Flamini, G. Natalini, G. Agnelli. (*Italy*)